Navigation Links
Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from,Human Clinical Trials for New Cancer Drug

PASADENA, Calif.--(BUSINESS WIRE)--Jun 1, 2007 - Arrowhead Research Corporation (Nasdaq:ARWR) announced today that interim Phase I data has been published in the 2007 American Society for Clinical Oncology Proceedings (ASCO) (Abstract ID 32638). The data are from an ongoing Phase I clinical study designed to evaluate the safety, tolerability, and pharmacokinetics of its lead anti-cancer drug candidate, IT-101, in patients with inoperable or metastatic tumors. IT-101 is a conjugate of the potent anti-cancer drug camptothecin and Insert's proprietary drug delivery technology, Cyclosert(TM).

"The interim IT-101 study results look very promising," stated R. Bruce Stewart, Chairman of Arrowhead. "We were encouraged to see patients who have failed other chemotherapies complete the whole six cycles of treatment without disease progression."

The abstract's authors state that the stable disease rate, although not yet conclusive, is consistent with promising efficacy. In general, IT-101 was well tolerated and pancytopenia was the dose limiting toxicity. Patients that have completed the six cycle treatment regimen and showed stable disease or better are expected to continue to receive treatment on a compassionate care basis. The first person to enter the trial, a pancreatic cancer patient, is stable after 10 months.

"The type of dose limiting toxicity identified is consistent with the expectation for a camptothecin derivative," said Dr. Thomas Schluep, Chief Scientific Officer at Insert. "We are encouraged that, at dose levels that have promising efficacy, we have not seen some of the other deleterious side effects commonly experienced by patients receiving camptothecin class drugs."

Pharmacokinetics data were favorable and consistent with results from preclinical animal studies. In the patients studied, IT-101 showed longer half life, lower clearance and lower volume of distribution than seen in pati ents treated with other camptothecin-based drugs. The study is ongoing and Insert expects to enter Phase II studies later this year or early next year.

"It is gratifying to see that the Cyclosert system is working as designed in patients," said Dr. Mark Davis, inventor of the technology and Insert's Scientific Founder. "We are looking forward to completing this trial and moving into multiple Phase II studies."

About Arrowhead Research Corporation

Arrowhead Research Corporation ( is a publicly-traded nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is building value for shareholders through the progress of majority owned subsidiaries founded on nanotechnologies originally developed at universities. The company works closely with universities to source early stage deals and to generate rights to intellectual property covering promising new nanotechnologies. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications, including anti-cancer drugs, RNAi therapeutics, carbon-based electronics and compound semiconductor materials.

About Insert Therapeutics

Insert Therapeutics, Inc. (, a majority-owned subsidiary of Arrowhead Research Corporation (NASDAQ:ARWR), is using its proprietary, nano-engineered, polymeric delivery system, Cyclosert(TM), to design, develop and commercialize drug-delivery-enhanced small-molecule therapeutics and nucleic acids. Cyclosert uses cyclodextrins as building blocks to create an entirely new class of biocompatible materials - linear cyclodextrin-containing polymers that are non-toxic and non-immunogenic at therapeutic doses. Insert's affiliate company, Calando Pharmaceuticals, is using a related system for the systemic delivery of siRNA. The companies are pursuing this goal through internal research and development, and also through collaborations and partnership s with pharmaceutical and biotechnology companies.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our clinical studies, our ability to successfully develop and manufacture products, rapid technological change in our industry, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, and other SEC filings discuss these and other important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.


Arrowhead Research Corporation
Virginia Dadey, 212-541-3707
Insert Therapeutics
Thomas Schluep, 626-683-7200


Related medicine technology :

1. Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting
2. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
3. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
4. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
5. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
6. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
7. The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
8. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
9. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
10. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
11. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
Post Your Comments:
(Date:11/30/2015)... 30, 2015 Diplomat Pharmacy, Inc. (NYSE: ... the Detroit Free Press as a Top Workplace , ... to work for in 2015. ... 100 winners annually, based on employee surveys rating company leadership, ... Workplaces are based solely on employee feedback. The survey is ...
(Date:11/30/2015)... , November 30, 2015 global cell ... of US$6.1 bn to US$11.3 bn by 2022 at a CAGR ... is expected to grow from its 2013 value of US$6.1 bn ... --> Transparency Market Research has announced the release of ... According to the report, titled ,Cell Culture Market - Global Industry ...
(Date:11/30/2015)... and BOCA RATON, Fla. , ... the Commercialization of Public Research (the Institute) announced ... KynderMed , a medical device start-up company with ... new company creation based on publicly-funded research, and bridges ... Florida -based universities and research institutions. ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... During the National ... caregivers and held two webinars on topics of ‘Medical and Palliative Care Decisions,’ ... at . , With a loved one's diagnosis of mesothelioma, the ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... . The directory is specialized and only includes chiropractic clinics in the US. ... competent and trustworthy alternative health practitioner when back pain sets in. When people ...
(Date:11/30/2015)... ... November 30, 2015 , ... In an effort ... the Word of Life Christian Church of Flint, MI, hosted a family-oriented evening ... 1.25 ton pile of candy dubbed “Candy Mountain”. , A Forever Recovery, a ...
(Date:11/30/2015)... VA (PRWEB) , ... November 30, 2015 , ... ... Foundation kicked off its annual fundraising campaign to raise funds for its research, ... raises approximately 10% of the organization’s annual funding. , The Mesothelioma Applied Research ...
(Date:11/30/2015)... ... November 30, 2015 , ... The ... in Dallas, TX, on January 29 and 30, 2016. The course welcomes dental ... of their practices, to learn how to better succeed in the modern dental ...
Breaking Medicine News(10 mins):